Dianthus Therapeutics Inc (NASDAQ:DNTH) price on Thursday, July 03, rose 2.56% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.85.
A look at the stock’s price movement, the close in the last trading session was $18.38, moving within a range at $18.105 and $19.015. Turning to its 52-week performance, $32.27 and $13.36 were the 52-week high and 52-week low respectively. Overall, DNTH moved 7.16% over the past month.
Dianthus Therapeutics Inc’s market cap currently stands at around $606.22 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-12.
Turning to the stock’s technical picture we see that short term indicators suggest on average that DNTH is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend DNTH as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
DNTH’s current price about 3.82% and -0.98% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.08, while 7-day volatility ratio is 6.16% and 6.32% in the 30-day chart. Further, Dianthus Therapeutics Inc (DNTH) has a beta value of 1.42. Analysts have given the company’s stock an average 52-week price target of $51.5, forecast between a low of $51 and high of $52. Looking at the price targets, the low is -170.56% off current price level while to achieve the yearly target high, price needs to move -175.86%. Nonetheless, investors will most likely welcome a -173.21% jump to $51.5 which is the analysts’ median price.
If we refocus on Dianthus Therapeutics Inc (NASDAQ:DNTH), historical trading data shows that trading volumes averaged 0.34 over the past 10 days and 319.30K over the past 3 months. The company’s latest data on shares outstanding shows there are 32.13 million shares.
The 30.61% of Dianthus Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 96.23% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.69 million on 2025-06-13, giving us a short ratio of 23.36. The data shows that as of 2025-06-13 short interest in Dianthus Therapeutics Inc (DNTH) stood at 2544.0 of shares outstanding, with shares short rising to 6.37 million registered in 2025-05-15. Current price change has pushed the stock -34.71% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DNTH stock continues to rise going into the next quarter.
